D7L1

Summary: This annotation correctly reflects the subcellular localization of D7L1 as a secreted salivary protein. The IBA annotation is based on phylogenetic inference (GO_REF:0000033) and is consistent with experimental data showing D7 proteins are secreted into saliva.

Reason: D7L1 is a secreted protein with a signal peptide (residues 1-21) [UniProt Q7PJ76]. It is released into the extracellular space (saliva) during blood feeding. The UniProt entry confirms "SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P18153}" [UniProt Q7PJ76]. This is an appropriate CC annotation consistent with the protein's function as a secreted kratagonist that sequesters host mediators at the feeding site.

Summary: This annotation is INCORRECT for D7L1. While the IBA annotation is based on phylogenetic inference from the PBP/GOBP family, D7L1 has evolved a completely different function. The protein is expressed in salivary glands, not olfactory tissues, and functions in blood feeding by sequestering host eicosanoids, not in olfaction.

Reason: D7L1 belongs to the PBP/GOBP structural family (InterPro IPR006170), which led to this IBA annotation based on phylogenetic inference. However, the D7 long-form proteins have evolutionarily repurposed this fold for binding eicosanoids (leukotrienes, thromboxane) in saliva, not odorants in antennae. UniProt explicitly describes D7L1's function: "Modulates blood feeding of female mosquitoes on vertebrate species by binding and sequestering different mediators involved in the host response" and "Binds leukotriene C4 and U-46619, a stable analog of thromboxane A2" [UniProt Q7PJ76, PMID:35460690]. The protein is expressed exclusively in female salivary glands, not olfactory tissues. GO:0007608 definition "The series of events required to receive an olfactory stimulus" does not apply - D7L1 has no role in olfaction. This is a clear case where structural homology (driving the IBA annotation) does not predict function.

Summary: This annotation accurately describes D7L1's function. The protein modulates host hemostatic and inflammatory responses during blood feeding by sequestering eicosanoids (leukotriene C4 and thromboxane A2). This is a correct BP annotation for the cross-species effect.

Reason: D7L1 clearly modulates processes in the vertebrate host. Per UniProt, it "Modulates blood feeding of female mosquitoes on vertebrate species by binding and sequestering different mediators involved in the host response" [UniProt Q7PJ76]. The GO:0035821 definition "A process in which an organism effects a change in a biological process in another organism" accurately captures this function. The annotation was inferred via GO_REF:0000108 from the toxin activity annotation, but the logic is sound - kratagonistic binding of host eicosanoids does modulate host processes. Specifically, D7L1 inhibits U-46619-induced platelet aggregation and exhibits vasodilating activity [PMID:35460690].

Summary: This annotation is INCORRECT based on structural family membership (PBP/GOBP family via InterPro IPR006170) but does not reflect the actual function of D7L1. The protein binds eicosanoids (leukotriene C4, thromboxane A2), not odorants, and has no role in olfaction.

Reason: D7L1 belongs to the PBP/GOBP structural family (InterPro IPR006170), which led to this IEA annotation. However, the D7 long-form proteins have evolutionarily repurposed this fold for binding eicosanoids in saliva, not odorants in antennae. D7L1 is expressed exclusively in female salivary glands, not olfactory tissues. The actual molecular function is icosanoid binding (GO:0050542) - specifically binding leukotriene C4 and thromboxane A2 analog U-46619 [PMID:35460690]. IMPORTANTLY: D7L1 does NOT bind biogenic amines (serotonin, histamine) - this is the key difference from short-form D7 proteins like D7r1. The GO:0005549 definition "Binding to an odorant, any substance capable of stimulating the sense of smell" does not apply - leukotriene C4 and thromboxane A2 are not odorants. UniProt explicitly states "Binds leukotriene C4 and U-46619, a stable analog of thromboxane A2" [PMID:35460690].

Proposed replacements: icosanoid binding

Summary: This annotation correctly reflects the subcellular localization of D7L1 as a secreted salivary protein. This is broader than GO:0005615 (extracellular space) but still accurate.

Reason: D7L1 is a secreted protein with a signal peptide (residues 1-21) [UniProt Q7PJ76]. It is released into the extracellular region (saliva) during blood feeding. The UniProt entry confirms "SUBCELLULAR LOCATION: Secreted" [UniProt Q7PJ76]. This is an appropriate CC annotation. Having both GO:0005576 (extracellular region) and GO:0005615 (extracellular space) is acceptable as they represent different levels of granularity.

Summary: This annotation is supported by experimental evidence. D7L1 exhibits vasodilating activity by sequestering vasoconstrictor eicosanoids (thromboxane A2), thereby preventing vasoconstriction at the feeding site.

Reason: UniProt explicitly states "Exhibits vasodilating activity (PubMed:35460690)" [UniProt Q7PJ76]. By binding and sequestering thromboxane A2 (tested using analog U-46619), D7L1 prevents this potent vasoconstrictor from acting on host blood vessels. The net effect is vasodilation at the feeding site, facilitating blood meal acquisition. GO:0042311 definition "The increase in the internal diameter of blood vessels" accurately describes the consequence of D7L1's kratagonist activity.

Summary: This annotation is an OVER-ANNOTATION. D7L1 does not meet the GO definition of toxin activity, which requires "initiating pathogenesis (leading to an abnormal, generally detrimental state)". D7L1 transiently modulates host physiology without causing disease or tissue damage.

Reason: The GO:0090729 definition states: "Interacting selectively with one or more biological molecules in another (target) organism, initiating pathogenesis (leading to an abnormal, generally detrimental state) in the target organism." D7L1 does NOT meet this definition because: (1) It does not initiate pathogenesis - it facilitates feeding, not disease; (2) It does not cause tissue damage - it transiently sequesters host eicosanoids; (3) The effect is reversible and temporary; (4) The host returns to normal state after feeding. The UniProt keywords "Hemostasis impairing toxin" and "Platelet aggregation inhibiting toxin" that led to this IEA annotation via GO_REF:0000043 are technically inaccurate - anti-hemostatic activity is not equivalent to toxin activity. The kratagonist mechanism (sequestering signaling molecules) is fundamentally different from true toxins that cause pathological damage. Better annotations would be icosanoid binding (GO:0050542) for MF, and negative regulation of hemostasis (GO:1900047) for BP.

Summary: This annotation is technically accurate but vague. D7L1 does affect blood vessel diameter by promoting vasodilation through sequestration of the vasoconstrictor thromboxane A2. However, GO:0042311 (vasodilation) is more specific and already annotated.

Reason: D7L1 affects blood vessel diameter by sequestering thromboxane A2 and preventing vasoconstriction, resulting in vasodilation [PMID:35460690, UniProt Q7PJ76]. GO:0097746 definition "Any process that modulates the diameter of blood vessels" is accurate but less specific than GO:0042311 (vasodilation) which is already annotated. This annotation can be kept as non-core since it provides additional context about the protein's role in vascular regulation, but GO:0042311 better captures the specific function.

Summary: D7L1 binds icosanoids (leukotriene C4 and thromboxane A2) with high affinity as demonstrated by direct binding assays. This is the core molecular function that should be annotated.

Reason: UniProt confirms "Binds leukotriene C4 and U-46619, a stable analog of thromboxane A2 (PubMed:35460690)" [UniProt Q7PJ76]. Both leukotriene C4 and thromboxane A2 are icosanoids (C20 polyunsaturated fatty acid derivatives). GO:0050542 definition "Binding to icosanoids, any C20 polyunsaturated fatty acids or their derivatives, including the leukotrienes and the prostanoids" accurately describes D7L1's molecular function. This is the actual binding activity that enables the kratagonist mechanism - sequestering host icosanoids to prevent their vasoconstrictive and platelet-aggregating effects. IMPORTANT: D7L1 specifically binds eicosanoids, NOT biogenic amines like serotonin or histamine (which are bound by short-form D7 proteins like D7r1).

Summary: D7L1 inhibits platelet aggregation by sequestering thromboxane A2, which represents negative regulation of hemostasis. This is a core biological process annotation.

Reason: UniProt states "Inhibits agonist-induced platelet aggregation (PubMed:35460690)" [UniProt Q7PJ76]. By sequestering thromboxane A2 (which promotes platelet aggregation), D7L1 negatively regulates the host hemostatic response. GO:1900047 definition "Any process that stops, prevents or reduces the frequency, rate or extent of hemostasis" accurately captures this function. This is a more accurate BP annotation than inferring from "toxin activity". The inhibition of U-46619-induced platelet aggregation is the key experimental evidence demonstrating this function [PMID:35460690].

Summary: D7L1 inhibits U-46619-induced platelet aggregation by sequestering thromboxane A2. This is a more specific annotation than negative regulation of hemostasis.

Reason: UniProt explicitly states "Inhibits agonist-induced platelet aggregation (PubMed:35460690)" [UniProt Q7PJ76]. The specific agonist is U-46619, a stable thromboxane A2 analog. By binding and sequestering thromboxane A2, D7L1 prevents it from activating platelet aggregation. GO:0090331 definition "Any process that decreases the rate, frequency or extent of platelet aggregation" accurately describes this function. This provides a more specific BP annotation than GO:1900047 (negative regulation of hemostasis).

Summary: D7L1 inhibits vasoconstriction by sequestering thromboxane A2 (tested using U-46619). This annotation captures the mechanism behind the vasodilating activity.

Reason: UniProt states "Exhibits vasodilating activity (PubMed:35460690)" [UniProt Q7PJ76]. The mechanism is through binding and sequestering thromboxane A2, preventing it from inducing vasoconstriction. GO:0045906 definition "Any process that stops, prevents, or reduces the frequency, rate or extent of vasoconstriction" accurately describes this function. This provides mechanistic context to the GO:0042311 (vasodilation) annotation.